Results 211 to 220 of about 180,427 (290)

Circulating CAR T‐Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B‐Cell Lymphomas and Its Association to Treatment Outcome

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives This study investigates the expansion of CAR T‐cells and its association to treatment outcome. Methods Patients with aggressive B‐cell lymphomas treated with anti‐CD19 CAR T‐cell therapy axicabtagene ciloleucel (axi‐cel) at Skåne and Sahlgrenska University Hospitals from 2019 to October 2024 were included.
Louise Olsson Werne   +6 more
wiley   +1 more source

Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL) is a rare subtype of large B‐cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with
Atte Karhu   +22 more
wiley   +1 more source

Double-hit primary high-grade gastric B-cell lymphoma presenting with pancytopaenia and atraumatic back pain: A case report. [PDF]

open access: yesWorld J Gastrointest Pharmacol Ther
Fu MY   +5 more
europepmc   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking   +6 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta   +14 more
wiley   +1 more source

Follicular lymphoma within an ovarian teratoma. [PDF]

open access: yesOxf Med Case Reports
Tchapdeu F   +3 more
europepmc   +1 more source

Cellular Morphometric Analysis (CellMorph)—a comprehensive imaging‐based tool for quantifying cellular phenotype heterogeneity and dynamics across biological processes

open access: yesThe FEBS Journal, EarlyView.
CellMorph is a groundbreaking tool that allows researchers to analyze multiple features from single cells, including cell size and shape, cytosolic staining and subcellular texture, nuclear staining, and morphometry. By evaluating images from both bright‐field and fluorescence microscopy, it also tracks changes in living cells during key processes such
Henrique Quaiato de Oliveira   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy